The Differences Between the Effect of Oral and Intraperitoneal Induction of Aluminum Chloride (AlCl3) on the Memory Function of White Rats (Rattus norvegicus strain wistar) Menopause Model


The decline in estrogen at menopause leads to a loss of neuroprotective function. One of the effects is Alzheimer’s disease (AD), with clinical manifestations of dementia, decreased memory function, language, thinking, and learning. The pathology of AD is widely studied but not completely understood. Various animal models have been used but have not been able to represent the pathology of AD fully. This study aimed to determine the effect of oral and intraperitoneal induction of aluminium chloride (AlCl3) on the memory function of menopausal model white rats (Rattus norvegicus strain wistar). This study used 16 female rats, divided into four groups, namely the negative control group (K1), the ovariectomy group (OVX, K2), and the OVX + AlCl.6H20 group 100 mg/kg BW orally (K3), and the OVX + AlCl3.6H20 group. 70 mg/kg body weight intraperitoneally. AlCl3.6H20 induction was given for six weeks. In the last five days, the Morris water maze test was carried out. From the MANOVA test, the p-value of F values in Pillai’s trace, Wilks‘ Lambda, Hotelling’a Trace, and Roy’s Largest Root were < 0.05. Based on the post hoc Bonferroni test on the fifth day of the trial, there was a significant difference between the standard and OVX groups with the AlCl3 induction group, and there was no significant difference between the oral and intraperitoneal induction groups. Conclusion: There is no significant effect of oral and intraperitoneal induction of Aluminum Chloride (AlCl3) on the memory function of white rats (Rattus norvegicus strain wistar) menopausal model.

Keywords: menopause, Alzheimer’s disease, memory test

[1] Murray MT. Alzheimer’s Disease [Internet]. Fourth Edition. Textbook of Natural Medicine. Elsevier; 1189–1199 p. Available from: 2333-5.00144-9.

[2] Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update [Internet]. Pharmacol Rep. 2015 Apr;67(2):195–203.

[3] Rather MA, Thenmozhi AJ, Manivasagam T, Bharathi MD, Essa MM, Guillemin GJ. Neuroprotective role of asiatic acid in aluminium chloride induced rat model of Alzheimer’s disease. Front Biosci - Sch. 2018;10(2):262–75.

[4] Saldanha CJ, Duncan KA, Walters BJ. Neuroprotective actions of brain aromatase [Internet]. Front Neuroendocrinol. 2009 Jul;30(2):106–18.

[5] Pompili A, Arnone B, Gasbarri A. Estrogens and memory in physiological and neuropathological conditions [Internet]. Psychoneuroendocrinology. 2012 Sep;37(9):1379–96.

[6] Pines A. Alzheimer’s disease, menopause and the impact of the estrogenic environment. Climacteric. 2016 Oct;19(5):430–2.

[7] Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R. Metal Toxicity Links to Alzheimer’s Disease and Neuroinflammation [Internet]. J Mol Biol. 2019 Apr;431(9):1843–68.

[8] Exley C, Mold MJ. Aluminium in human brain tissue: how much is too much? [Internet]. Eur J Biochem. 2019 Dec;24(8):1279–82.

[9] Ali AA, Ahmed HI, Abu-Elfotuh K. Modeling Stages Mimic Alzheimer’s Disease Induced by Different Doses of Aluminum in Rats: Focus on Progression of the Disease in Response to Time [Internet]. Available from:

[10] Amber S, Ali Shah S, Ahmed T, Zahid S. Syzygium aromaticum ethanol extract reduces AlCl3-induced neurotoxicity in mice brain through regulation of amyloid precursor protein and oxidative stress gene expression. Asian Pac J Trop Med. 2018 Feb;11(2):123–30.

[11] Ahmad Rather M, Justin-Thenmozhi A, Manivasagam T, Saravanababu C, Guillemin GJ, Essa MM. Asiatic Acid Attenuated Aluminum Chloride-Induced Tau Pathology, Oxidative Stress and Apoptosis Via AKT/GSK-3ß Signaling Pathway in Wistar Rats. Neurotox Res. 2019 May;35(4):955–68.

[12] Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017 Oct;24(5):101–5.

[13] Braidy N, Poljak A, Jayasena T, Mansour H, Inestrosa NC, Sachdev PS. Accelerating Alzheimer’s research through “natural” animal models. Current Opinion in Psychiatry. Lippincott Williams and Wilkins; 2015. p. 155–64.

[14] Green FML and KN. Animal models of Alzheimer. Nat Rev Neurosci. 2008;12(7):1123– 544.

[15] Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front Pharmacol. 2014 Jun;5( June):146.

[16] Kitazawa M, Medeiros R, Laferla FM. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des. 2012;18(8):1131–47.